Author: Avalon Health Economics LLC

Avalon’s Andrew Briggs Conducted Work on the Excess Mortality Attributable to COVID-19 Featured in the Wall Street Journal
May 5, 2020 - 9:47 am, by
The Wall Street Journal recently covered the work that Avalon’s Andrew Briggs conducted on the excess mortality attributable to COVID-19. Briggs put the U.S. average at almost 14 years lost and the U.K. average at almost 11 years.
Cost Impact Model of a Novel Multi-mRNA Host Response Assay for Diagnosis and Risk Assessment of Acute Respiratory Tract Infections and Sepsis in the Emergency Department
April 29, 2020 - 1:52 pm, by
The Avalon team helped Inflammatix, Inc., develop economic evidence for HostDx Sepsis test for the diagnosis of acute infections. A newly released publication describes a cost impact model comparing the cost of standard of care versus the use of HostDx Sepsis in two hypothetical arms with 1000 patients presenting with symptoms of ARTI in the...
Electronic Medical Records: Potential Issues in Litigation and Biomedical Research
April 27, 2020 - 12:06 pm, by
In this blog entry we explore some of the potentially important issues surrounding the role of EMRs in litigation, where the discovery of medical documents and records increasing involves digitally stored data.[1-4]
Estimating QALY Losses Associated With Deaths in Hospital (COVID-19)
April 17, 2020 - 4:50 pm, by
Avalon Director Andrew Briggs, DPhil, addresses the issue of potential losses in quality-adjusted life years (QALYs) associated with COVID-19.
Applications of HEOR Analytics: Covariate-Adjusted Analysis of Phase 3 Clinical Trial Data of Lenvatinib versus Sorafenib in Hepatocellular Carcinoma
April 17, 2020 - 9:09 am, by
In this blog entry we report on a good example of HEOR analytics: our recent study of covariate-adjusted analysis of trial data of lenvatinib versus sorafenib in hepatocellular carcinoma.
COVID-19: Update on Epidemiology & Costs
April 14, 2020 - 11:55 am, by
We define epidemiology broadly, including an up-to-date review of the key published medical literature on COVID-19. Following that, our discussion of costs focuses in part on the direct medical costs (which probably for good reasons has been relatively under-reported) and in part on the broader costs to the economy.
Distinguishing Between Viral and Bacterial Respiratory Infections
April 8, 2020 - 12:04 pm, by
Avalon researchers published important research on distinguishing between viral and bacterial respiratory infections, a topic that is of great importance given the COVID-19 pandemic. Check out the study at:
The Coronavirus: How Bad is it, Really?
March 13, 2020 - 4:06 pm, by
By: The Avalon Health Economics Team March 13, 2020 Within a few months we’ve gone from worrying about holiday shopping to worrying about global pandemics and watching the world shut down around us. It started with news from China on the rapid spread of an insidious virus initially called a coronavirus.[1] Once the virus was...
What is the Reasonable Value of Future Medical Care?
February 10, 2020 - 1:49 pm, by
Cara Scheibling and John Schneider, PhD February 7, 2020 A common challenge in economics and business is determining the fair-market value of products and services that have not yet “entered” the market.  If consumers have not yet signaled a “willingness to pay” for the product or service, it is difficult to predict the fair market...
How Important is ICER Preparation and Review for U.S. Market Access?
December 23, 2019 - 3:13 pm, by
John Schneider, PhD and Alexis Doyle, MA Avalon Health Economics December 23, 2019 In recent years in the U.S., there has been an increase in the use of cost-effectiveness analysis (CEA) for drug and medical device coverage decisions. While the Center for Medicare and Medicaid Services (CMS) remains considerably behind European countries in the use...
Avalon Health Economics LLC